



Salmonella enterica serovar Choleraesuis derivatives harbouring deletions in *rpoS* and *phoP* regulatory genes as vehicles for DNA vaccines

Almira Bartolomé¹, Aldara Herrero-Gil¹, Pilar Horcajo, José A. Orden, Ricardo de la Fuente, Gustavo Domínguez-Bernal^{*}

Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040 Madrid, Spain

ARTICLE INFO

Article history:

Received 17 April 2009

Received in revised form 9 July 2009

Accepted 3 August 2009

Keywords:

Salmonella Choleraesuis

Survival

Proliferation

Attenuated strain

Pigs

Vaccine vector

ABSTRACT

We investigated the use of two previously described attenuated strains of *Salmonella enterica* subspecies *enterica* serovar Choleraesuis (*S. Choleraesuis*), $\Delta phoP$ and $\Delta rpoS$, compared with the commercial attenuated SC-54 strain, as bactofection vehicles, to deliver an epitope model (3xFLAG) to the intestinal immune system. The gene encoding the epitope 3xFLAG was subcloned into the pCMV β m2A mammalian expression vector (creating pCMV3xFLAGm2A) and introduced into *S. Choleraesuis* strains. The 3xFLAG epitope was expressed efficiently in murine macrophage J774A.1 cell cultures infected with *Salmonella* $\Delta phoP$ and $\Delta rpoS$ vehicles but not with SC-54, as shown by gene-specific quantitative real-time reverse-transcriptase PCR. The stability of pCMV3xFLAGm2A in each strain was determined *in vitro* in the absence of antibiotic selection, and *in vivo* following oral immunisation of BALB/c mice. Administration of the DNA vaccine to mice led to the production of 3xFLAG-specific serum IgG and intestinal IgA antibody responses in $\Delta rpoS$ and SC-54, and spleen cell secretion of IFN- γ following specific 3xFLAG stimulation in $\Delta phoP$. All together, these results indicate that $\Delta phoP$, $\Delta rpoS$ and SC-54 that expressed 3xFLAG from pCMV3xFLAGm2A elicited a different biased immune response, in which the T-helper-1-like cellular immune response was predominant in $\Delta phoP$, whilst IgA-related mucosal immunity predominated in $\Delta rpoS$ and SC-54. We conclude that $\Delta phoP$ and $\Delta rpoS$ of *S. Choleraesuis* are new promising candidates as vaccine bactofection vectors.

© 2009 Elsevier B.V. All rights reserved.

1. Introduction

DNA vaccines offer several advantages over conventional methods of immunisation, in that they are easy to develop, are safe and well tolerated by laboratory and livestock animals, and are capable of stimulating cellular and humoral immune responses (Daudel et al., 2007). However, their relatively low efficacy, specifically in target species, is an important disadvantage, and several strate-

gies have been employed to overcome this major stumbling block of DNA vaccines. The major challenge to improving DNA-based vaccines is to increase its transfection efficiency (Dietrich et al., 2003; van Drunen Littel-van den Hurk et al., 2004). An attractive alternative is the mucosal delivery of plasmid DNA by orally administered intracellular bacteria (Dietrich et al., 2003).

Attenuated bacteria can transfer plasmids that encode foreign antigens under the control of eukaryotic promoters to the host cells, and are considered as ideal candidates for the delivery of DNA vaccines (bactofection) (Daudel et al., 2007). Careful selection of an appropriate carrier strain and its attenuated mutations is an important means to fine-tune the quality of the immune response. Among other

^{*} Corresponding author. Tel.: +34 913943712; fax: +34 913943908.

E-mail address: gdbernal@vet.ucm.es (G. Domínguez-Bernal).

¹ These authors contributed equally to the study.

Table 1

Bacterial strains and plasmids used in this study.

Strain or plasmid	Description and relevant characteristics	Source (reference)
<i>Salmonella enterica</i> serovar Choleraesuis		
CECT ^a 915	Wild-type	Spanish Culture Type Collection
SCL ^b 00031	$\Delta rpoS$ from CECT 915	Dominguez-Bernal et al. (2008)
SCL 00032	$\Delta phoP$ from CECT 915	Dominguez-Bernal et al. (2008)
SC-54	Commercial Live Vaccine Strain	Boehringer Ingelheim (Roof and Doitchinoff, 1995)
SCL 00071	Wild-type/pCMV β m2A, Amp ^R	This work
SCL 00072	Wild-type/pCMV3xFLAGm2A, Amp ^R	This work
SCL 00068	$\Delta rpoS$ /pCMV β m2A, Amp ^R	This work
SCL 00067	$\Delta rpoS$ pCMV3xFLAGm2A, Amp ^R	This work
SCL 00066	$\Delta phoP$ /pCMV β m2A, Amp ^R	This work
SCL 00064	$\Delta phoP$ pCMV3xFLAGm2A, Amp ^R	This work
SCL 00073	SC-54/pCMV β m2A, Amp ^R	This work
SCL 00072	SC-54/pCMV3xFLAGm2A, Amp ^R	This work
Plasmids		
pCMV β m2A	Amp ^R	Bauer et al. (2005), Datsenko and Wanner (2000)
pCMV3xFLAGm2A	Expressing 3xFLAG; Amp ^R	This work

^a CECT, Spanish collection of Type Cultures, Universidad de Valencia, Burjassot (Valencia), Spain.^b SCL, *Salmonella* Choleraesuis collection from the INBAVET group.

candidates, *Salmonella* has attracted considerable attention as an ideal orally administered antigen-delivery vector for plasmid DNA (Darji et al., 1997; Kwon et al., 2007). These *Salmonella*-based vaccines are fully capable of eliciting humoral, cell-mediated and mucosal immune responses, not only against their heterologous antigens, but also against the *Salmonella* carrier itself (Kwon et al., 2007).

We have recently reported the construction of two highly attenuated strains of *Salmonella* Choleraesuis, $\Delta rpoS$ and $\Delta phoP$, with excellent properties as candidates for vaccine vectors (Dominguez-Bernal et al., 2008).

In the present study, we exploited these strains of *S. Choleraesuis* as bacterofection vectors in a murine model. A previously described highly *Salmonella*-adapted eukaryotic expression low-copy-number vector, pCMV β m2A (Bauer et al., 2005), was chosen as a DNA delivery plasmid, which was administered to mice by the $\Delta rpoS$, $\Delta phoP$ and the commercial attenuated SC-54 *S. Choleraesuis* strains. After DNA immunisation by bacterofection, the mouse immune responses, including the systemic and mucosal antibody levels and T-cell response, were evaluated.

2. Materials and methods

2.1. Bacterial strains and growth conditions

The bacterial strains used in this study are listed in Table 1. *S. Choleraesuis* CECT 915 (ATCC 13312) was used as the wild-type (WT) strain. Bacteria were routinely cultured in Luria–Bertani (LB) broth and on LB agar plates. If required for the selection of recombinants or to maintain plasmids, 100 μ g/ml ampicillin (Amp) was added. The reference vaccine was a commercially available live avirulent culture (Enterisol[®] SC-54) and was obtained from Boehringer Ingelheim.

2.2. Construction of recombinant plasmid encoding 3xFLAG epitope

pCMV β m2A has been described previously (Bauer et al., 2005). For the cloning of the 3xFLAG fragment (encoding 3xFLAG) into pCMV β m2A, we first generated by PCR a 3xFLAG cassette by annealing the overlapping oligonucleotides: CFLA1D-X (Table 2) with a XhoI site and CFLA1D-N with a NotI site (Table 2). The amplicon was

Table 2

Primers used in this study.

Primer designation	Sequence (5' → 3') ^{a,b}	Orientation	Template plasmid/gene target
CFLA1D-X	CCGGTACTCGAGATGGACTACAAAGACCATGACGGTGATTA	Forward	
CFLA1D-N	TAAAGATCATGATATCGATTACAAGGATGACGATGACAAG GGATCCCGCGGCCGCTTGTCTATCGTCATCCTTGTAAATCGA TATCATGATCTTTATAATCACCGTCATGGTCTTTGTAGTCCAT	Reverse	
pcmv-1D	CCGCTTGTCTATCGTCATC	Forward	pCMV β m2A
pcmv-1R	GTTAACTTGTTTATTGCAGC	Reverse	pCMV β m2A
qFLAG-2D	GACTACAAAGACCATGACGG	Forward	3xFLAG
qFLAG-2R	GTCATCGTCATCCTTGTAAATC	Reverse	3xFLAG
qmBactin-1D	GGCACCACACCTTCTACAATG	Forward	Mouse β -actin (Register et al., 2007; Varona et al., 2005)
qmBactin-1R	TGGATGGCTACGTACATGGCT	Reverse	Mouse β -actin (Varona et al., 2005)

^a Enzyme restriction sites are underlined.^b Overlapping regions are depicted in bold.

Download English Version:

<https://daneshyari.com/en/article/2467986>

Download Persian Version:

<https://daneshyari.com/article/2467986>

[Daneshyari.com](https://daneshyari.com)